BR0313081A - Combinação de um inibidor de aromatase com um bisfosfanato - Google Patents

Combinação de um inibidor de aromatase com um bisfosfanato

Info

Publication number
BR0313081A
BR0313081A BR0313081-9A BR0313081A BR0313081A BR 0313081 A BR0313081 A BR 0313081A BR 0313081 A BR0313081 A BR 0313081A BR 0313081 A BR0313081 A BR 0313081A
Authority
BR
Brazil
Prior art keywords
aromatase inhibitor
disease
aromatase
combination
bisphosphanate
Prior art date
Application number
BR0313081-9A
Other languages
English (en)
Inventor
Ajay S Bhatnagar
Dean Brent Evans
Juerg Andreas Gasser
Jonathan Green
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0217636A external-priority patent/GB0217636D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0313081A publication Critical patent/BR0313081A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMBINAçãO DE UM INIBIDOR DE AROMATASE COM UM BISFOSFONATO". A presente invenção refere-se uma combinação para o tratamento de uma doença ou condição que responde à inibição de aromatase, em particular uma doença proliferativa, especialmente uma doença maligna como câncer de mama ou câncer sensível endócrino de tecido macio similar, o mais preferivelmente câncer de mama, compreendendo um inibidor de aromatase e um bisfosfonato para o uso simultâneo, concorrente, separado ou seq³encial na prevenção de perda óssea que é causada pelo tratamento com um inibidor de aromatase. Refere-se também a um método de tratar um paciente sofrendo de uma doença ou condição que responde à inibição de aromatase compreendendo administrar ao paciente uma quantidade eficaz de um bisfosfonato e uma quantidade eficaz de um inibidor de aromatase.
BR0313081-9A 2002-07-30 2003-07-29 Combinação de um inibidor de aromatase com um bisfosfanato BR0313081A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0217636A GB0217636D0 (en) 2002-07-30 2002-07-30 Organic compounds
US42548202P 2002-11-12 2002-11-12
PCT/EP2003/008377 WO2004012728A1 (en) 2002-07-30 2003-07-29 Combination of an aromatase inhibitor with a bisphosphonate

Publications (1)

Publication Number Publication Date
BR0313081A true BR0313081A (pt) 2005-07-12

Family

ID=31497252

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0313081-9A BR0313081A (pt) 2002-07-30 2003-07-29 Combinação de um inibidor de aromatase com um bisfosfanato

Country Status (12)

Country Link
US (1) US20060069067A1 (pt)
EP (1) EP1534265B1 (pt)
JP (1) JP2011057706A (pt)
CN (1) CN100593401C (pt)
AT (1) ATE345790T1 (pt)
AU (1) AU2003250190A1 (pt)
BR (1) BR0313081A (pt)
CA (1) CA2494345C (pt)
DE (1) DE60309887T2 (pt)
ES (1) ES2276119T3 (pt)
PT (1) PT1534265E (pt)
WO (1) WO2004012728A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0328040D0 (en) * 2003-12-03 2004-01-07 Coleman Robert E Pharmaceutical uses of bisphosphonates
WO2005117864A1 (en) * 2004-05-28 2005-12-15 Astrazeneca Ab Combination product comprising anastrozole and a dual prenyl transferase inhibitor
US20090215731A1 (en) 2005-10-19 2009-08-27 Chavah Pty Ltd. Reduction of Side Effects From Aromatase Inhibitors Used for Treating Breast Cancer
ES2953915T3 (es) 2014-10-22 2023-11-17 Havah Therapeutics Pty Ltd Métodos para reducir la densidad mamaria mamográfica y/o el riesgo de cáncer de mama
CN108472302A (zh) 2015-10-22 2018-08-31 哈瓦赫治疗有限公司 降低乳房摄影乳腺密度和/或乳腺癌风险的方法
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR THE DEGRADATION OF TARGET PROTEINS
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2018237026A1 (en) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS
EP3710002A4 (en) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
WO2019191112A1 (en) 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
CN112312904A (zh) 2018-04-16 2021-02-02 C4医药公司 螺环化合物
WO2020243777A1 (en) 2019-06-03 2020-12-10 Havah Therapeutics Pty Ltd Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use
WO2023014590A1 (en) * 2021-08-05 2023-02-09 Celanese Eva Performance Polymers Llc Implantable medical device for the delivery of bisphosphonate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617307A (en) * 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
DE3428524A1 (de) * 1984-08-02 1986-02-13 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4749713A (en) * 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
DE3626058A1 (de) * 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
EP0275821B1 (de) * 1986-11-21 1992-02-26 Ciba-Geigy Ag Neue substituierte Alkandiphosphonsäuren

Also Published As

Publication number Publication date
ATE345790T1 (de) 2006-12-15
DE60309887D1 (de) 2007-01-04
EP1534265A1 (en) 2005-06-01
EP1534265B1 (en) 2006-11-22
JP2011057706A (ja) 2011-03-24
US20060069067A1 (en) 2006-03-30
DE60309887T2 (de) 2007-05-16
PT1534265E (pt) 2007-02-28
WO2004012728A1 (en) 2004-02-12
CA2494345C (en) 2011-11-29
CA2494345A1 (en) 2004-02-12
ES2276119T3 (es) 2007-06-16
CN100593401C (zh) 2010-03-10
CN1671371A (zh) 2005-09-21
AU2003250190A1 (en) 2004-02-23

Similar Documents

Publication Publication Date Title
BRPI0413255A (pt) uso de uma combinação de um inibidor de quinase do receptor do fator de crescimento epidérmico e agentes citotóxicos para tratamento e inibição do cáncer
BR0313081A (pt) Combinação de um inibidor de aromatase com um bisfosfanato
MX2010006519A (es) Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina.
UA94899C2 (ru) Фиксированное дозирование антител к her
WO2004043374A3 (en) Methods and compositions for treating cancer using proteasome inhibitors
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
WO2007079202A3 (en) Treatment for acute lymhoblastic leukemia
BR0308663A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas
BR0307629A (pt) Métodos e composições para tratar condições hiperproliferativas
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
EA201400423A1 (ru) Фармацевтические препараты и их применение при лечении половой дисфункции у женщин
BRPI0408491A (pt) tratamento da doença de alzheimer
BR0312929A (pt) Uso de um composto, e, métodos de tratamento, prevenção ou alìvio de uma doença, distúrbio ou condição de um corpo de animal vivo, e da degeneração macular relacionada com a idade de um corpo de animal vivo
GB0020504D0 (en) Therapeutic method
EA200501456A1 (ru) Торий- 227 для применения в радиотерапии заболевания мягких тканей
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
WO2008060535A3 (en) Use of reversine and analogs for treatment of cancer
BR0315374A (pt) Compostos orgânicos
TNSN06147A1 (en) Use of cathepsin k inhibitors for treating of severe bone loss diseases
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture
TW200512183A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of frailty, muscle damage or sarcopenia
HUP9903685A2 (hu) Olanzapin alkalmazása túlzott agresszivitás kezelésére szolgáló gyógyszerkészítmények előállítására
BR0308105A (pt) Composição farmacêutica compreendendo um bisfosfonato e um inibidor de cox-2 para o tratamento de doenças de ossos
WO2006034325A3 (en) Method of treatment for or protection against lymphedema
TW200511998A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of anorexia or low bone mass in females exhibiting aggressive athletic behavior

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2265 DE 03/06/2014.